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Abstract 
Sedation for pediatric cardiac catheteriza-
tion is a common requirement in many institu-
tions. As the field of cardiac catheterization
has evolved, the provision of sedation for these
procedures has been varied. Increasingly the
demand is for dedicated personnel focused on
monitoring and delivery of sedation while in
the  catheterization  suite.  This  article
describes  the  considerations  one  must  use
when undertaking these cases. 
Introduction
Modern  pediatric  cardiac  catheterization
began with in 1947 when Bing described using
catheterization  for  diagnosis  of  congenital
heart disease. In the ensuing period, echocar-
diography has become increasing refined and
has supplanted the need for many diagnostic
catheterizations.  However,  interventional
catheterizations  have  increasingly  become  a
mainstay of pediatric care. Pediatric interven-
tional catheterization began in earnest in 1968
with  balloon  atrial  septostomy1 and  quickly
became  a  common  procedure  in  pediatric
catheterization. Numerous advances occurred
in the 1980s and 1990s. Modern pediatric car-
diac catheterization can now treat a number of
conditions including patent ductus arteriosus,
atrial septal defects, ventricular septal defects,
collateral vessels, valve stenosis, vessel steno-
sis, and conduction abnormalities. Increasing
minimally-invasive  procedures  has  strained
the  traditional  model  of  anesthesia-directed
care in the operating room environment with a
variety of providers now administering analge-
sia and sedation for children.2 Pediatric heart
catheterizations have increased exponentially
in  recent  years.3 Sedation  has  traditionally
been  under  the  direction  of  the  performing
cardiologist.  However,  the  need  to  have  the
patient  be  motionless  has  increased  as  the
number  of  interventions  has  increased.  In
addition, there is increased recognition that
dedicated personnel focused on monitoring of
the  patient  during  sedation  are  associated
with improved safety. As the demand for seda-
tion  outside  of  the  operating  room  has
increased, a number of providers have gained
experience in providing for the sedation and
analgesia of these patients. In addition to a
number  of  different  provider  models,  wide
variations exist in approaches to sedation reg-
imens.4 The different types of practitioners as
well as the special circumstances that accom-
pany congenital heart disease require special
emphasis.
Composition of sedation team
A striking variety of practice models exist in
pediatric catheterization suites. Depending on
the  practice  setting,  pediatric  cardiologists,
registered nurses, Certified Registered Nurse
Anesthetist’s (CRNA), anesthesiologists, hos-
pitalists, pediatric emergency physicians, and
pediatric intensivists may perform the primary
role of sedation. Regardless of the provider, it
is essential that safe and effective sedation be
practiced.  Debate  continues  for  and  against
non-anesthesiologists performing these seda-
tions.5-7 Regardless of the team composition,
consistency  in  NPO  guidelines,  monitoring,
and ability for resuscitation must be kept. The
reader is referred to excellent general guide-
lines  available  through  the  2006  American
Academy of Pediatric Sedation Guidelines and
the  2002  American  Society  for  Anesthesio  -
logists  Practice  Guidelines  for  Sedation  and
Analgesia by Non-Anesthesio  logists.8,9
Pre-procedural considerations
Prior to sedation, adequate consideration of
a patient’s physiologic status must be under-
taken. Important features include underlying
physiology, comorbidities and procedure to be
performed. Some cooperative patients (older
children and adults with congenital heart dis-
ease) may be able to have anxiolysis or light
sedation  and  achieve  excellent  outcomes.
Younger  children  will  however  require  deep
sedation (minimal response to painful stim-
uli) at least initially. The goals of catheteriza-
tion must be reviewed (Table 1).
Congenital heart disease
Patients with congenital heart lesions are a
common group of children undergoing pedi-
atric cardiac catheterization. Understanding of
the specific lesion and how hypotension, hypo-
or hypercarbia, and supplemental oxygen alter
the patient’s hemodynamics is critical. Volume
status changes and afterload alterations can
severely alter the physiology of both cyanotic
and acyanotic lesions.
Included in the preoperative checklist is a
review of the latest echocardiogram, hospital
history, and previous surgical procedures.
The authors strongly recommend that seda-
tion is undertaken only by practitioners inti-
mately familiar with the cardiovascular physi-
ology of these conditions. Choices such as sup-
plemental oxygen, assisted or mechanical ven-
tilation changes in acid-base status, and alter-
ations  of  systemic  and  pulmonary  vascular
resistance will alter interpretation of diagnos-
tic data.
Interventional catheterization
Interventional catheterizations require spe-
cial  consideration.  The  technical  nature  of
these  procedures  demands  minimal  sponta-
neous  movement.  Many  interventions  are
more painful (e.g. aortic angioplasty) than a
diagnostic catheterization; requiring substan-
tially  more  attention  to  analgesic  needs.  In
addition,  closure  devices  for  atrial  septal
defects and ventricular septal defects alter the
hemodynamics of the patient. Relatively high
complication rates are associated with closure
devices  that  alter  sedation  management.10,11
The  practitioner  must  be  able  to  rapidly
address  cardiorespiratory  changes  in  these
patients. As with all deep sedations, expertise
in  airway  management  and  intubation  is  a
must.12
Radiofrequency ablation
The  need  for  sedation  has  increased  as
techniques  for  radiofrequency  ablation  have
advanced. Many of these children have con-
genital heart disease, in addition to managing
the  arrhythmia-induced  cardiovascular
changes  that  are  prerequisite  with  these
patients. These patients also have longer pro-
cedure times than other candidates for proce-
dural  sedation.  Joung  et  al  found  that  their
procedure times for atrial tachycardias aver-
aged 131.0±48.8 minutes. However, they also
found  that  the  procedure  time  was  reduced
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when the patient received sedation rather than
general anesthesia.13 Concerns that the seda-
tion or anesthesia regimen may alter the con-
duction pathways and invalidate the electro-
physiology study may be exaggerated.14,15
Goals of catheterization
As with any procedure, the sedation tech-
nique will vary depending on the goal of the
procedure.  For  instance,  in  a  diagnostic
catheterization  to  determine  the  degree  of
reversible pulmonary vascular disease, multi-
ple  variables  would  need  to  be  considered.
Hypo- or hyperventilation, supplemental oxy-
gen, and acid-base status need to be manipu-
lated. Therapeutic agents that alter vascular
tone will ultimately alter the interpretation of
the study.16 The prodecuralists must communi-
cate their interventions with particular atten-
tion paid to the ramifications on the patient’s
hemodynamics. 
Sedation regimens
The ideal sedative agent does not exist.
Demerol, Phenergan and Thorazine 
Traditionally,  agents  such  as  Demerol,
Phenergan, and Thorazine (DPT) have been
used in pediatric catheterizations. Benefits of
its use included oral or intramuscular adminis-
tration.  However,  variable  efficacy  and  a
marked  complication  and  side  effect  profile
have been documented. Other oral agents have
been documented to have superior efficacy to
DPT.17 In  2005,  the  American  Academy  of
Pediatrics retired its policy on DPT and instead
wrote  Neither  the  combination  itself  nor  its
dosage is based on sound pharmacologic data.
There is a high rate of therapeutic failure as
well as a high rate of serious adverse reactions,
including  respiratory  depression  and  death,
associated with its use. Even when it is effec-
tive, DPT appears to lack many of the desirable
characteristics of a sedative for children.
While many practitioners may have experi-
ence and expertise using this combination of
medications,  this  regimen  is  likely  to  have
greater complications and adverse effects than
other regimens. In 2004, a black box warning
was  added  to  promethazine  contraindicating
its use in children under 2 years of age second-
ary  to  the  severe  adverse-events,  including
death.  Most  practitioners  have  discontinued
this practice.
Midazolam
Midazolam is a short-acting benzodiazepine
with a large body of evidence in pediatric care.
Among the reason for midazolam’s popularity
is its ability to be given through a variety of
routes,  including  nasal  administration.
Commercially, it is the most commonly used
pediatric premedication for generalized anes-
thesia.18 In the anesthetic setting, premedica-
tion with midazolam has no significant car-
diorespiratory  effects.19 While  an  effective
anxiolytic  in  most  children,  a  significant
minority  of  children  have  extreme  distress
nonetheless.20
Midazolam has been successfully used as a
solo agent for pediatric catheterization. Jobier
et al. describe a cohort of 35 patients within a
group of 154 patients who received midazolam
0.14 mg/kg/hr intravenously without complica-
tions.21 Unfortunately in this study, there was
no criteria as to what criteria supported the
used of midazolam as an only agent.
Ketamine
Ketamine is a hypnotic/sedative medication
preferred by many in pediatric catheterization
suites.22 Among its benefits is the ability to
protect airway reflexes with minimal effect on
respiration  with  preserved  cardiac  function.
Concerns regarding emergence reactions have
limited  its  usage.  However,  in  a  study  by
Karapinar et al., emergence reactions occurred
in less than 2%. Some clinicians co-administer
midazolam to prevent these reactions; howev-
er, the efficacy of this practice has been debat-
ed.23
Although  some  tout  ketamine  as  having
minimal  hemodynamic  effect,  ketamine  can
significantly  alter  catheterization  data.22
Ketamine preserves cardiac function through
increased sympathetic effects. Whether keta-
mine increases pulmonary vascular resistance
remains to be elucidated.24 Some have seen
increases in systemic vascular resistance also.
For instance, ketamine is frequently used with
lesions such as aortic stenosis in which exces-
sive  afterload  reduction  may  be  deleterious.
Other sedation regimens may be better suited
for  other  lesions,  which  cannot  tolerate
increases in afterload, such as mitral regurgi-
tation.
Propofol
The commercial availability of propofol in
1989  brought  the  ability  to  induce  general
anesthesia outside of the confines of the oper-
ating  room.  Expensive  inhaled  anesthesia
machines  and  scavenger  devices  introduced
the concept of safari teams.25 In addition, non-
anesthesiologists  became  increasingly  com-
fortable  with  this  medication  and  propofol
services were introduced.26
It is important to note there are currently
three preparations of propofol approved for use
by the FDA. One of these preparations uses
benzyl alcohol as its emulsion agent. Infants
have had significant toxicity and even death as
a result of high doses given as a preservative.
Propofol  has  a  number  of  properties  that
make it advantageous over other sedation reg-
imens. It has many, but not all, of the proper-
ties of an ideal sedative drug. It has a pre-
dictable onset of action, a short half-life with a
rapid  recovery  time,  and  is  easily  titratable.
However, propofol is associated with profound
respiratory depression outside of a fairly nar-
row therapeutic window. Like all of the seda-
tive regimens listed here, propofol provides no
analgesic activity. In fact, there is some evi-
dence  that  propofol  given  in  sub-anesthetic
doses  induces  hyperalgesia.27 In  addition,
propofol induces clinically relevant changes in
cardiac index with decreases in afterload and
preload.28
Prolonged  propofol  sedation  should  not
occur in children. In 2001, the FDA issued a
black box warning which reported the results
of a study of 327 sedated patients in pediatric
intensive care units treated with either propo-
fol or standard sedative agents. In this unpub-
lished study, a significantly higher number of
patients died in the propofol arms of the study.
Many speculate that the increased incidence of
mortality may be due to propofol infusion syn-
drome. The syndrome, characterized by a pro-
found metabolic acidosis, rhabdomyolysis, and
ensuing  death  was  first  described  in  chil-
dren.29 The mechanism of action, thought to
be  mitochondrial  poisoning,  has  yet  to  be
elicited.  In  adults,  recent  reports  show  that
even short-term administration of propofol can
cause a metabolic acidosis.30 These findings
are also present in children undergoing car-
diac  catheterization  (unpublished  data  –
Turner). Some believe this acidosis may be an
early  indication  of  propofol  infusion  syn-
Article
Table 1. Goals of catheterization.
1. Analgesia, anxiolysis, and amnesia for patient
2. Easy separation from parents at start of case 
3. Maintain airway and appropriate ventilation
4. Monitor and maintain appropriate acid-base status
5. Minimize cardiovascular stress on the patient 
6. Optimize hemodynamic status before, during, and after the procedure, tailored to the 
specific physiology of the individual patient
7. Immobilization for precision, particularly when interventions are needed
8. Smooth transition to awake state after procedure, minimizing cardiovascular stress upon 
awakening (avoiding/minimizing agitation, hypertension, coughing fits, tachycardia, etc)
9. Provide appropriate conditions for obtaining useful cath data (i.e. testing with nitric oxide, valsalva, 
spontaneous breathing vs positive pressure ventilation, etc) [Pediatric Reports 2011; 3:e23] [page 95]
drome.31
In the setting of pediatric catheterization,
propofol (usually in combination with an anal-
gesic) has been used with increasing frequen-
cy. In practice, PVR remains constant; while
SVR decreases.32 Diagnostic data needs to be
interpreted  with  this  in  mind  as  this  does
decrease shunt ratios. In addition to patients
with  cardiomyopathies,  congenital  cyanotic
heart lesions may be particularly susceptible to
deterioration.33
Propofol and ketamine
In an effort to preserve SVR while retaining
the positive aspects of propofol (quick onset of
action,  predictable  response,  rapid  recovery
time), some practices have incorporated the
addition of ketamine infusions.34,35 Ketamine
and  propofol  have  opposing  influences  on
blood pressure, heart rate, and SVR. In addi-
tion, ketamine supplementing a propofol infu-
sion has been shown to preserve respiratory
function and upper airway control in several
studies.34,36 Recovery times were 20 minutes
in  a  group  of  children  given  propofol  at  25
ug/kg/min  with  the  addition  of  ketamine  at
12.5 ug/kg/minute.34
Dexmedetomidine
Dexmedetomidine is a a2 agonist sedative
and  mild  analgesic  approved  by  the  FDA  in
1999 which preserves cardiorespiratory func-
tion. It has similar actions to clonidine, anoth-
er a2 agonist. However, dexmedetomidine has
a short half-life elimination of 6 minutes and
terminal  half-life  of  2  hours.  Although
approved for mechanically ventilated adults for
periods  less  than  24  hours,  experience  is
increasing  in  using  this  medication  in  chil-
dren. Over 2300 sedations have been reported
to the pediatric sedation research consortium
(Berkenbosch – unpublished data).
Munro et al sedated 20 children for cardiac
catheterization  with  dexmedetomidine.37
Patients were given 1 ug/kg loading dose over
10  minutes  followed  by  an  infusion  of  1
ug/kg/hr.  Of  these  20  patients,  12  patients
required  a  bolus  of  propofol  for  movement,
increasing BIS values, or prior to stimulation.
The  patients  had  stable  hemodynamics
throughout. 
Tosun et al. compared the combination of
dexmedetomidine-ketamine  to  propofol-keta-
mine  in  44  patients.38 Two  regimens  were
compared: 
1. dexmedetomidine  0.7  ug/kg  loading  dose
over 10 minutes followed by an infusion of 1
ug/kg/hr and ketamine 1mg /kg bolus with 1
mg/kg/hr infusion
2. propofol 1mg/kg bolus followed by an infu-
sion of 100 ug/kg/min and ketamine 1 mg
/kg bolus with 1mg/kg/hr infusion
In  the  Tosun  study,  patients  on  the
dexmedetomidine regimen required more sup-
plemental  doses  of  ketamine  for  discomfort.
No  differences  in  side  effects  were  noted,
including  hypotension.  In  addition,  recovery
times were significantly longer (45 v. 20 min-
utes; P=0.01)
To  date,  no  studies  have  been  performed
which  examine  the  effects  of  dexmedetomi-
dine alone or in combination with other seda-
tives on pediatric catheterization data includ-
ing SVR and shunt ratios.
Etomidate
Etomidate is another medication, which has
recently fallen out of favor. Documentation of
adrenal  axis  suppression  as  well  as  painful
induction has decreased its usage in intensive
care settings. However, in some institutions,
its favorable hemodynamic profile has made it
a  common  medication  among  children  with
reserved hemodynamic function. Sarkar et al.
examined the hemodynamic responses to 12
children  undergoing  pediatric  cardiac
catheterization for ablation of superventricular
tachycarida or ASD closure. There were no sig-
nificant changes in hemodynamic profiles in
these children.39
Analgesics
Control of pain is an essential component to
a  well-performed  sedation.  The  provision  of
sedative  agents  does  not  provide  for  pain
relief. Some agents (e.g. propofol) have hyper-
gesic properties. This must be tempered with
the  realization  that  the  addition  of  opioid
agents may act synergistically other sedative
agents. Topical agents such as EMLA and LMX-
4  as  well  as  subcutaneous  local  anesthetics
can  dramatically  decrease  the  need  for  sys-
temic agents. Many our patients require mini-
mal sedation following administration of local
lidocaine and catheter insertion. Some older
patients  may  tolerate  a  catheterization  with
minimal sedation if their pain needs are cared
for.
Special considerations
Regardless of the sedation regimen imple-
mented,  pediatric  cardiac  patients  have
unique  characteristics  that  need  to  be
acknowledged.  For  example,  the  addition  of
supplemental  oxygen  can  dramatically  alter
cardiac output, as well as alter the interpreta-
tion of catheterization data. Alterations in ven-
tilation with positive pressure, hypo- or hyper-
ventilation  may  alter  pulmonary  blood  flow,
again leading to data that may be difficult to
interpret
Consideration must be taken into the length
of the procedure. Recent reports highlight the
potential deleterious effects of sedatives such
as ketamine, propofol, and midazolam on the
developing brain.40,41 As the length of the pro-
cedure increases, attention to metabolic sub-
strates (i.e. glucose), environmental stresses,
temperature regulation, and pulmonary toilet
must be addressed. Coordination of the seda-
tion procedurals with the cardiologist is a must
to ensuring optimal outcomes.
Post-sedation care is a continuation of the
procedure.  Qualified  personnel,  trained  in
resuscitation from deep sedation and general
anesthesia, as well as knowledgeable of con-
genital  heart  defects,  should  monitor  these
patients until ready for ultimate disposition. 
Conclusions
Advances in pediatric catheterization have
increased  the  demand  and  complexity  of
patients  undergoing  these  procedures.  This
patient population presents unique challenges
due to the large variability of their underlying
anatomy  and  physiology.  Sedation  regimens
are  varied,  with  importance  to  the  hemody-
namic profile of the patients. Dedicated seda-
tion  teams  are  a  necessary  requirement  to
optimal performing catheterization labs. 
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